Results 241 to 250 of about 38,540 (306)

Elranatamab: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Elranatamab (ELREXFIO) is a humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM). Elranatamab engages CD3 on T cells and B‐cell maturation antigen (BCMA) on myeloma cells to induce T cell–mediated myeloma cell cytolysis.
Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Pooneh Soltantabar, Hoi‐Kei Lon, Kamrine Poels, Blerta Shtylla, Donald Irby, Kristin Bompiani‐Myers, Thomas O'Brien, Jennifer Hibma   +10 more
wiley   +1 more source

Successful targeting of multidrug-resistant tumors with bispecific antibodies. [PDF]

MAbs
Briante R, Zhai Q, Mohanty S, Zhang P, O'Connor A, Misker H, Wang W, Tan C, Abuhay M, Morgan J, Theolis R, Ponath P, Arathoon R.   +12 more
europepmc   +1 more source

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, Volume 53, Issue 5, Page 422-426, May 2026.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source

Bispecific Antibodies in Glioblastoma: Mechanistic Advances, Delivery Innovations, and Translational Challenges in Overcoming Immune Escape. [PDF]

Int J Med Sci
Wang HL, Chi N, Zhang HT.
europepmc   +1 more source

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment

European Journal of Haematology, Volume 116, Issue 5, Page 577-584, May 2026.
ABSTRACT Background Severe renal insufficiency requiring dialysis in newly diagnosed multiple myeloma (NDMM) patients has been independently associated with poor survival outcomes. However, there is a paucity of data on factors predicting renal recovery and survival outcomes of these patients.
Rintu Sharma, Eshetu G. Atenafu, Esther Masih‐Khan, Harjot Vohra, Sita Bhella, Christine Chen, Vishal Kukreti, Guido Lancman, Anca Prica, A. Keith Stewart, Rodger Tiedemann, Suzanne Trudel, Chloe Yang, Donna Reece   +13 more
wiley   +1 more source

Erratum to "Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies" [Biomol Ther 32(6), 708-722 (2024)]. [PDF]

Biomol Ther (Seoul)
Choi SM, Lee JH, Ko S, Hong SS, Jin HE.
europepmc   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, Volume 116, Issue 5, Page 522-534, May 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US. [PDF]

Future Oncol
Mulvey E, Shafrin J, Than KS, Muthukrishnan S, Mutebi A, Chhibber A, Wang A, Alshreef A, Harb D, Gonzalez V, Quinlan S, Patel V, Johnson PC.   +12 more
europepmc   +1 more source

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. [PDF]

Blood Adv
Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano De Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B.   +31 more
europepmc   +1 more source